

Remarks

Claims 32, 41, 50, 59, 66 and 78 have been amended in order to more particularly point out and distinctly claim subject matter of the present invention. Support for amendment of claims 32, 41, 50, 59, 66 and 78 may be found throughout the specification as originally filed. On entry of the present amendment, claims 25-79 will be pending in this application. No new matter has been added by amendment.

Amendment of Claims

As requested by the Examiner in a telephone conversation with the undersigned on September 3, 2002, Applicants have amended claims 32, 41, 50, 59, 66 and 78 to recite "and an acceptable carrier."

Power of Attorney


In response to the Examiner's inquiry as to the status of the undersigned in the present application, Applicants enclose a copy of the Associate Power of Attorney previously filed in the present application on September 4, 2001. Said Associate Power of Attorney appointed all registered Practitioners at Customer No. 22195 as associate attorneys in the prosecution of the present application. Accordingly, the undersigned, as a registered Practitioner at Customer No. 22195, has been appointed an associate attorney with power to prosecute to present application.

Conclusion

Applicants respectfully request consideration and entry of the foregoing remarks into the file. Applicants believe that no fee is due in connection herewith; however, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Dated: September 4, 2002


Janet M. Martineau (Reg. No 46,903)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 315-2723 (telephone)

Enclosures
JMM/BM

Via FACSIMILE SEPTEMBER 4th, 2002**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: SU et al.

Application Serial No.: 09/416,267

Art Unit: 1646

Filed: October 12, 1999

Examiner: Mertz, P.

For: Human Cytokine Polypeptide

Attorney Docket No.: PF270P1

VERSION WITH MARKINGS SHOWING CHANGES MADE***In the Claims:***

Pending claims 32, 41, 50, 59, 66 and 78 have been replaced with the following rewritten claims:

32. (Once Amended) A composition comprising the isolated protein of claim 25 and an acceptable carrier.

41. (Once Amended) A composition comprising the isolated protein of claim 34 and an acceptable carrier.

50. (Once Amended) A composition comprising the isolated protein of claim 43 and an acceptable carrier.

59. (Once Amended) A composition comprising the isolated protein of claim 52 and an acceptable carrier.

66. (Once Amended) A composition comprising the isolated protein of claim

61 and an acceptable carrier.

78. (Once Amended) A composition comprising the isolated protein of claim
68 and an acceptable carrier.